Novo Nordisk

Urbanization And Aging Trends Will Amplify GLP-1 Adoption

AnalystHighTarget

Not Invested

Community Contributor

Published

30 May 25

AnalystHighTarget's Fair Value

DKK 612.00

43.7% undervalued

10 Sep

DKK 344.65

-56.8%

-8.0%

-56.8%

-8.0%

You can edit this narrative until May 30 9:16 PM. Then, changes will post as Updates.

Author's Valuation

DKK 61243.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

DKK 612

43.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.38%

Pharma revenue growth rate

0.67%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

DKK 167.49b

Earnings '28

18.64x

PE Ratio '28

DKK 3.12t

Market Cap '28

DKK 3.12t

Market Cap '28

4.42b

No. shares '28

DKK 706.66

Share Price '28

DKK 706.66 Share Price '28

Discounted to 2025 @ 4.92% p.a.

DKK 611.87

Fair Value '25